Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | DGKZ | Q13574 | 12/20 | 0.35 |
| ▸ | DGKA | P23743 | 11/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | HPD | P32754 | 2/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311431 | 0.83 | PDE3B (0.44) | ADORA2BBRD4BRPF1PIK3CDPIK3CA | |
| SCHEMBL29311430 | 0.77 | GRM2 (0.43) | ADORA2BDGKZ | |
| SCHEMBL23510554 | 0.74 | CDK4 (0.44) | — | |
| SCHEMBL29310609 | 0.72 | GSK3B (0.36) | DGKZDGKAPIK3CDPIK3CAPIK3CG | |
| SCHEMBL27446378 | 0.70 | HPD (0.46) | BRD4BRPF1MAPK14HPDBCL6 | |
| SCHEMBL27446315 | 0.70 | MAPK14 (0.43) | BRD4BRPF1MAPK14HPDBCL6 | |
| SCHEMBL29311703 | 0.70 | PIK3CA (0.41) | DGKZPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL27253861 | 0.70 | HSD17B10 (0.42) | ADORA2BMAPK14PIK3CABCL6PGR | |
| SCHEMBL22038880 | 0.69 | ADORA2B (0.45) | ADORA2BMAPK14BCL6 | |
| SCHEMBL27252322 | 0.69 | GSK3B (0.37) | DGKZDGKAPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ADORA2B 757/4885DGKZ 2546/4885DGKA 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.